Why the study?
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil and cisplatin chemotherapy for carcinoma?
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil and cisplatin chemotherapy for carcinoma?
Treatment with 5-fluorouracil and cisplatin is associated with a 15% incidence of cardiotoxicity, highlighting the need for close clinical and ECG monitoring during therapy.
15% cardiotoxicity incidence with 5-FU/cisplatin warrants monitoring; Level 3 data leave open whether baseline CVD modifies risk.
Cardiotoxicity of 5-fluorouracil and cisplatin chemotherapy for esophageal, head and neck and gastric carcinoma was studied. Before treatment all patients had a cardiac evaluation and during treatment serial electrocardiographic (ECG) recordings were performed. In the pre-treatment evaluation signs of cardiovascular disease were found in 31(38.75%) patients. During treatment cardiotoxicity was observed in 12(15%) patients. The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation. The most common signs of cardiotoxicity were chest pain, ST-T wave changes and arrhythmia. This study suggests that patients on 5-fluorouracil and cisplatin treatment should be under close supervision and that the treatment should be discontinued if chest pain and/or arrhythmias are observed.
No takes yet. Share an insight, caveat, or question.
Jeremić et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: